UNSPSC 51453018: Piperazine sulfate

This classification denotes an antihelminthic agent with the molecular formula C4H10N2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8493J9B36. The term dipiperazine sulfate is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule piperazine sulfate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE SULFATE remains US FDA's Preferred Term for this commodity. Piperazine sulfate bears US NLM identifiers UMLS ID C0892285 and NCI Concept Code C81514. SMILES: C1CNCCN1.OS(=O)(=O)O.

UNSPSC 51453018 Piperazine sulfate is a Commodity code that captures pharmaceutical chemical compounds and active pharmaceutical ingredients procured by state and local health agencies for clinical, emergency response, and public health programs. Recent state and local solicitations under this code show procurement of specific pharmaceuticals — including antibiotic tablets, opioid antagonists, and drug deactivation systems — sourced through both direct purchase and cooperative purchasing arrangements. The issuing bodies are state health departments and county public health or emergency services divisions, which use competitive bidding (IFB and ITB processes) and piggyback agreements with established pharmaceutical consortiums to acquire inventory on fixed-term contracts with renewal options. Scope of work centers on volume pharmaceutical supply with defined expiration windows, quarterly or annual delivery schedules to health facilities, and compliance requirements including drug-free workplace certification and E-Verify documentation.

Recent activity appears concentrated in the Southeast and Midwest. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC (awarded August 28, 2026) for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets under a 12-month term with two renewal options. Seminole County, Florida, issued an IFB (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, vendor-responsible shipping included, on a two-year initial term with a one-year renewal option. These opportunities reflect the code's active use for both routine pharmaceutical supply and emergency-response inventory across state health departments and county health authorities.